Intermediate stage hepatocellular carcinoma: a summary review

References

• Levi Sandri GB, Ettorre GM, Aldrighetti L, et al. Laparoscopic liver resection of hepatocellular carcinoma located in unfavorable segments: a propensity score-matched analysis from the I Go MILS (Italian group of minimally invasive liver surgery) registry. Surg Endosc. 2019;33(5):1451–1458. doi:10.1007/s00464-018-6426-3
   Web of Science ®Google Scholar
• Galle PR, Tovoli F, Foerster F, Wörns MA, Cucchetti A, Bolondi L. The treatment of intermediate stage tumours beyond TACE: from surgery to systemic therapy. J Hepatol. 2017;67:173–183. doi:10.1016/j.jhep.2017.03.00728323121
   PubMed Web of Science ®Google Scholar
• Golfieri R, Bargellini I, Spreafico C, et al. Patients with barcelona clinic liver cancer stages B and C hepatocellular carcinoma: time for a subclassification. Liver Cancer. 2019;8:78–91. doi:10.1159/000489791.
   Web of Science ®Google Scholar
• Guo JG, Zhao LP, Rao YF, et al. Novel multimodal analgesia regimen improves post TACE pain in patients with hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2018. doi:10.1016/j.hbpd.2018.08.001
   Web of Science ®Google Scholar
• Iezzi R, Cesario V, Siciliani L, et al. Single-step multimodal locoregional treatment for unresectable hepatocellular carcinoma: balloon-occluded percutaneous radiofrequency thermal ablation (BO-RFA) plus transcatheter arterial chemoembolization (TACE). Radiol Med. 2013;118:555–569. doi:10.1007/s11547-012-0914-723358819
   PubMed Web of Science ®Google Scholar
• Guo W, He X, Li Z, et al. Combination of transarterial chemoembolization (TACE) and radiofrequency ablation (RFA) vs. Surgical Resection (SR) on survival outcome of early hepatocellular carcinoma: a meta-analysis. Hepatogastroenterology. 2015;62:710–714.26897959
   PubMedGoogle Scholar
• Piscaglia F, Ogasawara S. Patient selection for transarterial chemoembolization in hepatocellular carcinoma: importance of benefit/risk assessment. Liver Cancer. 2018;7:104–119. doi:10.1159/00048547129662837
   PubMed Web of Science ®Google Scholar
• Pinato DJ, Howell J, Ramaswami R, Sharma R. Review article: delivering precision oncology in intermediate-stage liver cancer. Aliment Pharmacol Ther. 2017;45:1514–1523. doi:10.1111/apt.1406628440552
   PubMed Web of Science ®Google Scholar
• White JA, Gray SH, Li P, et al. Current guidelines for chemoembolization for hepatocellular carcinoma: room for improvement?. Hepatol Commun 2017;1:338–346.
   Google Scholar
• Groszmann RJ, Garcia-Tsao G, Bosch J, et al. Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med. 2005;353:2254–2261. doi:10.1056/NEJMoa04445616306522
   PubMed Web of Science ®Google Scholar
• Bolondi L, Burroughs A, Dufour JF, et al. Heterogeneity of patients with intermediate (BCLC B) hepatocellular carcinoma: proposal for a subclassification to facilitate treatment decisions. Semin Liver Dis. 2012;32:348–359. doi:10.1055/s-0032-132990623397536
   PubMed Web of Science ®Google Scholar
• Budny A, Kozlowski P, Kaminska M, et al. [Epidemiology and risk factors of hepatocellular carcinoma]. Pol Merkur Lekarski. 2017;43:133–139.28987047
   PubMedGoogle Scholar
• Ghouri YA, Mian I, Rowe JH. Review of hepatocellular carcinoma: epidemiology, etiology, and carcinogenesis. J Carcinog. 2017;16:1. doi:10.4103/jcar.JCar_9_1628694740
   PubMedGoogle Scholar
• Zhou Y, Si X, Wu L, Su X, Li B, Zhang Z. Influence of viral hepatitis status on prognosis in patients undergoing hepatic resection for hepatocellular carcinoma: a meta-analysis of observational studies. World J Surg Oncol. 2011;9:108. doi:10.1186/1477-7819-9-10821933440
   PubMed Web of Science ®Google Scholar
• Waked I, Berhane S, Toyoda H, et al. Transarterial chemo-embolisation of hepatocellular carcinoma: impact of liver function and vascular invasion. Br J Cancer. 2017;116:448–454. doi:10.1038/bjc.2016.42328125820
   PubMed Web of Science ®Google Scholar
• WHO. European Status Report on Alcohol and Health 2010. 2010.
   Google Scholar
• Ahmad W, Ijaz B, Gull S, et al. A brief review on molecular, genetic and imaging techniques for HCV fibrosis evaluation. Virol J. 2011;8:53. doi:10.1186/1743-422X-8-5321299910
   PubMed Web of Science ®Google Scholar
• Raoul J-L, Gilabert M, Piana G. How to define transarterial chemoembolization failure or refractoriness: a European perspective. Liver Cancer. 2014;3:119–124. doi:10.1159/00034386724945002
   PubMed Web of Science ®Google Scholar
• Shim JH, Lee HC, Kim SO, et al. Which response criteria best help predict survival of patients with hepatocellular carcinoma following chemoembolization? A validation study of old and new models. Radiology. 2012;262:708–718. doi:10.1148/radiol.1111028222187634
   PubMed Web of Science ®Google Scholar
• Kim BK, Kim SU, Kim KA, et al. Complete response at first chemoembolization is still the most robust predictor for favorable outcome in hepatocellular carcinoma. J Hepatol. 2015;62:1304–1310. doi:10.1016/j.jhep.2015.01.02225637785
   PubMed Web of Science ®Google Scholar
• Lencioni R, Llovet JM, Han G, et al. Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: the SPACE trial. J Hepatol. 2016;64:1090–1098. doi:10.1016/j.jhep.2016.01.01226809111
   PubMed Web of Science ®Google Scholar
• Kudo M. Heterogeneity and subclassification of barcelona clinic liver cancer stage B. Liver Cancer. 2016;5:91–96. doi:10.1159/00036776827386427
   PubMed Web of Science ®Google Scholar
• Vincenzi B, Di Maio M, Silletta M, et al. Prognostic relevance of objective response according to EASL criteria and mRECIST criteria in hepatocellular carcinoma patients treated with loco-regional therapies: a literature-based meta-analysis. PLoS One. 2015;10:e0133488. doi:10.1371/journal.pone.013348826230853
   PubMed Web of Science ®Google Scholar
• Wang W, Bai W, Wang E, et al. mRECIST response combined with sorafenib-related adverse events is superior to either criterion alone in predicting survival in HCC patients treated with TACE plus sorafenib. Int J Cancer. 2017;140:390–399. doi:10.1002/ijc.3045127681592
   PubMed Web of Science ®Google Scholar
• Wang X, Wang Z, Wu L. Combined measurements of tumor number and size helps estimate the outcome of resection of barcelona clinic liver cancer stage B hepatocellular carcinoma. BMC Surg. 2016;16:22. doi:10.1186/s12893-016-0135-427094483
   PubMed Web of Science ®Google Scholar
• Campani C, Vitale A, Dragoni G, et al. Time-varying mHAP III is the most accurate score in predicting survival in patients with hepatocellular carcinoma (HCC) undergoing trans-arterial chemoembolization (TACE). Digestive Liver Dis. 2019;51:e6. doi:10.1016/j.dld.2018.11.047
   Web of Science ®Google Scholar
• Burrel M, Reig M, Forner A, et al. Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using drug eluting beads. Implications for clinical practice and trial design. J Hepatol. 2012;56:1330–1335. doi:10.1016/j.jhep.2012.01.00822314428
   PubMed Web of Science ®Google Scholar
• Malagari K, Pomoni M, Moschouris H, et al. Chemoembolization with doxorubicin-eluting beads for unresectable hepatocellular carcinoma: five-year survival analysis. Cardiovasc Intervent Radiol. 2012;35:1119–1128. doi:10.1007/s00270-012-0394-022614031
   PubMed Web of Science ®Google Scholar
• Cabibbo G, Genco C, Di Marco V, et al. Predicting survival in patients with hepatocellular carcinoma treated by transarterial chemoembolisation. Aliment Pharmacol Ther. 2011;34:196–204. doi:10.1111/j.1365-2036.2011.04694.x21564144
   PubMed Web of Science ®Google Scholar
• Chung GE, Lee J-H, Kim HY, et al. Transarterial chemoembolization can be safely performed in patients with hepatocellular carcinoma invading the main portal vein and may improve the overall survival. Radiology. 2011;258:627–634. doi:10.1148/radiol.1010105821273524
   PubMed Web of Science ®Google Scholar
• Hucke F, Pinter M, Graziadei I, et al. How to STATE suitability and START transarterial chemoembolization in patients with intermediate stage hepatocellular carcinoma. J Hepatol. 2014;61:1287–1296. doi:10.1016/j.jhep.2014.07.00225016222
   PubMed Web of Science ®Google Scholar
• Sieghart W, Hucke F, Pinter M, et al. The ART of decision making: retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma. Hepatology. 2013;57:2261–2273. doi:10.1002/hep.2625623316013
   PubMed Web of Science ®Google Scholar
• Cai XR, Chen ZH, Liu MM, et al. Modified CLIP score with the albumin-bilirubin grade retains prognostic value in HBV-related hepatocellular carcinoma patients treated with trans-catheter arterial chemoembolization therapy. J Cancer. 2018;9:2380–2388. doi:10.7150/jca.2292530026834
   PubMed Web of Science ®Google Scholar
• Carling U, Rosok B, Line PD, et al. ALBI and P-ALBI grade in Child-Pugh A patients treated with drug eluting embolic chemoembolization for hepatocellular carcinoma. Acta Radiol. 2018;60(6):702–709. 30205701
   PubMed Web of Science ®Google Scholar
• Elshaarawy O, Alkhatib A, Elhelbawy M, et al. Validation of modified albumin-bilirubin-TNM score as a prognostic model to evaluate patients with hepatocellular carcinoma. World J Hepatol. 2019;11(6):542-552.
   Google Scholar
• Ho CHM, Chiang CL, Lee FAS, et al. Comparison of platelet-albumin-bilirubin (PALBI), albumin-bilirubin (ALBI), and child-pugh (CP) score for predicting of survival in advanced hcc patients receiving radiotherapy (RT). Oncotarget. 2018;9:28818–28829. doi:10.18632/oncotarget.2552229988960
   PubMedGoogle Scholar
• Kadalayil L, Benini R, Pallan L, et al. A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancer. Ann Oncol. 2013;24:2565–2570. doi:10.1093/annonc/mdt24723857958
   PubMed Web of Science ®Google Scholar
• Park Y, Kim SU, Kim BK, et al. Addition of tumor multiplicity improves the prognostic performance of the hepatoma arterial-embolization prognostic score. Liver Int. 2016;36:100–107. doi:10.1111/liv.12878
   PubMed Web of Science ®Google Scholar
• Cappelli A, Cucchetti A, Cabibbo G, et al. Refining prognosis after trans-arterial chemo-embolization for hepatocellular carcinoma. Liver Int. 2016;36:729–736. doi:10.1111/liv.1302926604044
   PubMed Web of Science ®Google Scholar
• Op Den Winkel M, Nagel D, Op Den Winkel P, et al. The munich-transarterial chemoembolisation score holds superior prognostic capacities compared to TACE-tailored modifications of 9 established staging systems for hepatocellular carcinoma. Digestion;2018 1–12. 10.1159/000493136
   Web of Science ®Google Scholar
• Op Den Winkel M, Nagel D, Op Den Winkel P, et al. Transarterial chemoembolization for hepatocellular carcinoma: development and external validation of the munich-TACE score. Eur J Gastroenterol Hepatol. 2018;30:44–53. doi:10.1097/MEG.000000000000100529076939
   PubMed Web of Science ®Google Scholar
• Arizumi T, Ueshima K, Iwanishi M, et al. Evaluation of ART scores for repeated transarterial chemoembolization in Japanese patients with hepatocellular carcinoma. Oncology. 2015;89(Suppl 2):4–10. doi:10.1159/000440625
   Web of Science ®Google Scholar
• Kloeckner R, Pitton MB, Dueber C, et al. Validation of clinical scoring systems ART and ABCR after transarterial chemoembolization of hepatocellular carcinoma. J Vasc Interv Radiol. 2017;28:94–102. doi:10.1016/j.jvir.2016.06.01227562621
   PubMed Web of Science ®Google Scholar
• Mahringer-Kunz A, Kloeckner R, Pitton MB, et al. Validation of the risk prediction models STATE-score and START-strategy to guide TACE treatment in patients with hepatocellular carcinoma. Cardiovasc Intervent Radiol. 2017;40:1017–1025. doi:10.1007/s00270-017-1606-428197830
   PubMed Web of Science ®Google Scholar
• Adhoute X, Penaranda G, Naude S, et al. Retreatment with TACE: the ABCR SCORE, an aid to the decision-making process. J Hepatol. 2015;62:855–862. doi:10.1016/j.jhep.2014.11.01425463541
   PubMed Web of Science ®Google Scholar
• Pinato DJ, Arizumi T, Allara E, et al. Validation of the hepatoma arterial embolization prognostic score in European and Asian populations and proposed modification. Clin Gastroenterol Hepatol. 2015;13:1204–8 e2. doi:10.1016/j.cgh.2014.11.03725528009
   PubMed Web of Science ®Google Scholar
• Pinato DJ, Arizumi T, Jang JW, et al. Combined sequential use of HAP and ART scores to predict survival outcome and treatment failure following chemoembolization in hepatocellular carcinoma: a multi-center comparative study. Oncotarget. 2016;7:44705–44718. doi:10.18632/oncotarget.960427244889
   PubMedGoogle Scholar
• Pipa-Muniz M, Castells L, Pascual S, et al. The ART-SCORE is not an effective tool for optimizing patient selection for DEB-TACE retreatment. A multicentre Spanish study. Gastroenterol Hepatol. 2017;40:515–524. doi:10.1016/j.gastrohep.2017.05.00928676199
   PubMed Web of Science ®Google Scholar
• Terzi E, Terenzi L, Venerandi L, et al. The ART score is not effective to select patients for transarterial chemoembolization retreatment in an Italian series. Dig Dis. 2014;32:711–716. doi:10.1159/00036800725376288
   PubMed Web of Science ®Google Scholar
• Hiraoka A, Kumada T, Kudo M, et al. Hepatic function during repeated TACE procedures and prognosis after introducing sorafenib in patients with unresectable hepatocellular carcinoma: multicenter analysis. Dig Dis. 2017;35:602–610. doi:10.1159/00048025629040999
   PubMed Web of Science ®Google Scholar
• Kohla MAS, Abu Zeid MI, Al-Warraky M, Taha H, Gish RG. Predictors of hepatic decompensation after TACE for hepatocellular carcinoma. BMJ Open Gastroenterol. 2015;2:e000032. doi:10.1136/bmjgast-2015-000032
   Google Scholar
• Lencioni R, de Baere T, Burrel M, et al. Transcatheter treatment of hepatocellular carcinoma with doxorubicin-loaded DC bead (DEBDOX): technical recommendations. Cardiovasc Intervent Radiol. 2011;35:980–985. doi:10.1007/s00270-011-0287-722009576
   PubMed Web of Science ®Google Scholar
• Facciorusso A, Di Maso M, Muscatiello N. Drug-eluting beads versus conventional chemoembolization for the treatment of unresectable hepatocellular carcinoma: A meta-analysis. Digestive Liver Dis. 2016;48:571–577. doi:10.1016/j.dld.2016.02.005
   Web of Science ®Google Scholar
• Facciorusso A. Drug-eluting beads transarterial chemoembolization for hepatocellular carcinoma: current state of the art. World J Gastroenterol. 2018;24:161–169. doi:10.3748/wjg.v24.i2.16129375202
   PubMed Web of Science ®Google Scholar
• Sakr OS, Berndt S, Carpentier G, Cuendet M, Jordan O, Borchard G. Arming embolic beads with anti-VEGF antibodies and controlling their release using LbL technology. J Control Release. 2016;224:199–207. doi:10.1016/j.jconrel.2016.01.01026780173
   PubMed Web of Science ®Google Scholar
• Lahti S, Ludwig JM, Xing M, et al. In vitro biologic efficacy of sunitinib drug-eluting beads on human colorectal and hepatocellular carcinoma-A pilot study. PLoS One. 2017;12:e0174539. doi:10.1371/journal.pone.017453928384190
   PubMed Web of Science ®Google Scholar
• Salem R, Lewandowski RJ, Kulik L, et al. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology. 2011;140:497–507.e2. doi:10.1053/j.gastro.2010.10.04921044630
   PubMed Web of Science ®Google Scholar
• Salem R, Gordon AC, Mouli S, et al. Y90 radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology. 2016;151:1155–1163.e2. doi:10.1053/j.gastro.2016.08.02927575820
   PubMed Web of Science ®Google Scholar
• Kim H-C. Radioembolization for the treatment of hepatocellular carcinoma. Clin Mol Hepatol. 2017;23:109–114. doi:10.3350/cmh.2017.000428494530
   PubMed Web of Science ®Google Scholar
• Yin L, Li H, Li A-J, et al. Partial hepatectomy vs. transcatheter arterial chemoembolization for resectable multiple hepatocellular carcinoma beyond milan criteria: A RCT. J Hepatol. 2014;61:82–88. doi:10.1016/j.jhep.2014.03.01224650695
   PubMed Web of Science ®Google Scholar
• Hsu C-Y, Huang Y-H, Hsia C-Y, et al. A new prognostic model for hepatocellular carcinoma based on total tumor volume: the taipei integrated scoring system. J Hepatol. 2010;53:108–117. doi:10.1016/j.jhep.2010.01.03820451283
   PubMed Web of Science ®Google Scholar
• Yao Q, Zhang H, Xiong B, et al. Combination of sorafenib and TACE inhibits portal vein invasion for intermediate stage HCC: a single center retrospective controlled study. Oncotarget. 2017;8:79012–79022. doi:10.18632/oncotarget.2074529108283
   PubMedGoogle Scholar
• Kamo N, Kaido T, Yagi S, Okajima H, Uemoto S. Liver transplantation for intermediate-stage hepatocellular carcinoma. Liver Cancer. 2018;7:179–189. doi:10.1159/00048705829888207
   PubMed Web of Science ®Google Scholar
• D’Avola D, Iñarrairaegui M, Pardo F, et al. Prognosis of hepatocellular carcinoma in relation to treatment across BCLC stages. Ann Surg Oncol. 2011;18:1964–1971. doi:10.1245/s10434-011-1551-421267791
   PubMed Web of Science ®Google Scholar
• Morimoto M, Numata K, Kondou M, Nozaki A, Morita S, Tanaka K. Midterm outcomes in patients with intermediate-sized hepatocellular carcinoma: a randomized controlled trial for determining the efficacy of radiofrequency ablation combined with transcatheter arterial chemoembolization. Cancer. 2010;116:5452–5460. doi:10.1002/cncr.2531420672352
   PubMed Web of Science ®Google Scholar
• Veltri A, Moretto P, Doriguzzi A, Pagano E, Carrara G, Gandini G. Radiofrequency thermal ablation (RFA) after transarterial chemoembolization (TACE) as a combined therapy for unresectable non-early hepatocellular carcinoma (HCC). Eur Radiol. 2006;16:661–669. doi:10.1007/s00330-005-0029-916228211
   PubMed Web of Science ®Google Scholar
• Cabibbo G, Tremosini S, Galati G, et al. Transarterial chemoembolization and sorafenib in hepatocellular carcinoma. Expert Rev Anticancer Ther. 2014;14:831–845. doi:10.1586/14737140.2014.92069424850249
   PubMed Web of Science ®Google Scholar
• Chao Y, Chung Y-H, Han G, et al. The combination of transcatheter arterial chemoembolization and sorafenib is well tolerated and effective in Asian patients with hepatocellular carcinoma: final results of the START trial. Int J Cancer. 2015;136:1458–1467. doi:10.1002/ijc.2912625099027
   PubMed Web of Science ®Google Scholar
• Li L, Zhao W, Wang M, et al. Transarterial chemoembolization plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review and meta-analysis. BMC Gastroenterol. 2018;18:138. doi:10.1186/s12876-018-0863-230180810
   PubMed Web of Science ®Google Scholar
• Meyer T, Fox R, Ma YT, et al. Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial. Lancet Gastroenterol Hepatol. 2017;2:565–575. doi:10.1016/S2468-1253(17)30156-528648803
   PubMed Web of Science ®Google Scholar
• Pawlik TM, Reyes DK, Cosgrove D, et al. Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma. J Clin Oncol. 2011;29:3960–3967. doi:10.1200/JCO.2011.37.102121911714
   PubMed Web of Science ®Google Scholar
• Li C, Zhang W, Zhang R, Zhang L, Wu P, Zhang F. Therapeutic effects and prognostic factors in high-intensity focused ultrasound combined with chemoembolisation for larger hepatocellular carcinoma. Eur J Cancer. 2010;46:2513–2521. doi:10.1016/j.ejca.2010.06.01520663659
   PubMed Web of Science ®Google Scholar
• Dendy MS, Ludwig JM, Stein SM, Kim H. Locoregional therapy, immunotherapy and the combination in hepatocellular carcinoma: future directions. Liver Cancer. 2019;1–15. doi:10.1159/00049484330815391
   PubMed Web of Science ®Google Scholar
• Slovak R, Ludwig JM, Gettinger SN, Herbst RS, Kim HS. Immuno-thermal ablations - boosting the anticancer immune response. J Immunother Cancer. 2017;5:78. doi:10.1186/s40425-017-0284-829037259
   PubMed Web of Science ®Google Scholar
• Duffy AG, Ulahannan SV, Makorova-Rusher O, et al. Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma. J Hepatol. 2017;66:545–551. doi:10.1016/j.jhep.2016.10.02927816492
   PubMed Web of Science ®Google Scholar
• Hasdemir DB, Davila LA, Schweitzer N, et al. Evaluation of CT vascularization patterns for survival prognosis in patients with hepatocellular carcinoma treated by conventional TACE. Diagn Interv Radiol. 2017;23:217–222. doi:10.5152/dir.2016.1600628256449
   PubMed Web of Science ®Google Scholar
• Wiesner R, Edwards E, Freeman R, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 2003;124:91–96. doi:10.1053/gast.2003.50016
   Google Scholar
• Hayes CN, Zhang P, Zhang Y, Chayama K. Molecular mechanisms of hepatocarcinogenesis following sustained virological response in patients with chronic hepatitis C virus infection. Viruses. 2018;10:531. doi:10.3390/v10100531
   Web of Science ®Google Scholar
• Mabed M, Esmaeel M, El-Khodary T, Awad M, Amer T. A randomized controlled trial of transcatheter arterial chemoembolization with lipiodol, doxorubicin and cisplatin versus intravenous doxorubicin for patients with unresectable hepatocellular carcinoma. Eur J Cancer Care (Engl). 2009;18:492–499. doi:10.1111/j.1365-2354.2008.00984.x19453695
   PubMed Web of Science ®Google Scholar
• Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359:1734–1739. doi:10.1016/S0140-6736(02)08649-X12049862
   PubMed Web of Science ®Google Scholar
• Meyer T, Kirkwood A, Roughton M, et al. A randomised phase II/III trial of 3-weekly cisplatin-based sequential transarterial chemoembolisation vs embolisation alone for hepatocellular carcinoma. Br J Cancer. 2013;108:1252–1259. doi:10.1038/bjc.2013.8523449352
   PubMed Web of Science ®Google Scholar
• Yu SC, Hui JW, Hui EP, et al. Unresectable hepatocellular carcinoma: randomized controlled trial of transarterial ethanol ablation versus transcatheter arterial chemoembolization. Radiology. 2014;270:607–620. doi:10.1148/radiol.1313049824126369
   PubMed Web of Science ®Google Scholar
• Kolligs FT, Bilbao JI, Jakobs T, et al. Pilot randomized trial of selective internal radiation therapy vs. chemoembolization in unresectable hepatocellular carcinoma. Liver Int. 2015;35:1715–1721. doi:10.1111/liv.1275025443863
   PubMed Web of Science ®Google Scholar
• Golfieri R, Giampalma E, Renzulli M, et al. Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma. Br J Cancer. 2014;111:255–264. doi:10.1038/bjc.2014.19924937669
   PubMed Web of Science ®Google Scholar
• Brown KT, Do RK, Gonen M, et al. Randomized Trial of hepatic artery embolization for hepatocellular carcinoma using doxorubicin-eluting microspheres compared with embolization with microspheres alone. J Clin Oncol. 2016;34:2046–2053. doi:10.1200/JCO.2015.64.082126834067
   PubMed Web of Science ®Google Scholar
• Kudo M, Han G, Finn RS, et al. Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: A randomized phase III trial. Hepatology. 2014;60:1697–1707. doi:10.1002/hep.2729024996197
   PubMed Web of Science ®Google Scholar
• Wang H, Liu Y, Wang X, et al. Randomized clinical control study of locoregional therapy combined with arsenic trioxide for the treatment of hepatocellular carcinoma. Cancer. 2015;121:2917–2925. doi:10.1002/cncr.2945626033499
   PubMed Web of Science ®Google Scholar
• Pinter M, Ulbrich G, Sieghart W, et al. Hepatocellular carcinoma: a phase II randomized controlled double-blind trial of transarterial chemoembolization in combination with biweekly intravenous administration of bevacizumab or a placebo. Radiology. 2015;277:903–912. doi:10.1148/radiol.201514214026131911
   PubMed Web of Science ®Google Scholar
• Lencioni R, Cioni D. RFA plus lyso-thermosensitive liposomal doxorubicin: in search of the optimal approach to cure intermediate-size hepatocellular carcinoma. Hepat Oncol. 2016;3:193–200. doi:10.2217/hep-2016-000530191041
   PubMed Web of Science ®Google Scholar
• Liu D, Li H, Li P, et al. Evaluation of TACE combined with RFA and PEI in treating advanced hepatic carcinoma. J Interventional Radiol. 2009;18:389–391.
   Google Scholar
• Zhao M, Wang JP, Li W, et al. [Comparison of safety and efficacy for transcatheter arterial chemoembolization alone and plus radiofrequency ablation in the treatment of single branch portal vein tumor thrombus of hepatocellular carcinoma and their prognosis factors]. Zhonghua Yi Xue Za Zhi. 2011;91:1167–1172.21756768
   PubMedGoogle Scholar
• Huang D, Chen Y, Chen S, et al. TACE plus percutaneous chemotherapy-lipiodol treatment of unresectable pedunculated hepatocellular carcinoma. Medicine (Baltimore). 2017;96:e7650. doi:10.1097/MD.000000000000765028746230
   PubMed Web of Science ®Google Scholar